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Abstract
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective
microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling
pathways has become a novel therapeutic approach in CLL. The tyrosine kinase inhibitor dasatinib inhibits migration of
several cell lines from solid-organ tumours, but effects on CLL cells have not been reported. We studied the effect of
clinically achievable concentrations of dasatinib on signaling induced by the chemokine CXCL12 through its’ receptor
CXCR4, which is highly expressed on CLL cells. Dasatinib pre-treatment inhibited Akt and ERK phosphorylation in CLL cells
upon stimulation with CXCL12. Dasatinib also significantly diminished the rapid increase in actin polymerisation observed in
CLL cells following CXCL12 stimulation. Moreover, the drug significantly inhibited chemotaxis in a transwell assay, and
reduced the percentage of cells able to migrate beneath a CXCL12-expressing murine stromal cell line. Dasatinib also
abrogated the anti-apoptotic effect of prolonged CXCL12 stimulation on cultured CLL cells. These data suggest that
dasatinib, akin to other small molecule kinase inhibitors targeting the B-cell receptor signaling pathway, may redistribute
CLL cells from protective tissue niches to the peripheral blood, and support the investigation of dasatinib in combination
strategies.
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Introduction
It has long been appreciated that chronic lymphocytic
leukaemia (CLL) cells are dependent on a number of microenvi-
ronmental stimuli for survival and proliferation [1]. The
chemokine CXCL12, the ligand for the receptor CXCR4, has a
key physiological role in controlling mature B lymphocyte
trafficking through germinal centres [2]. CLL cells express high
levels of functional CXCR4 [3]; signaling through this receptor
reduces spontaneous and drug-induced apoptosis [4] and also
facilitates CLL cell migration beneath stromal cells [3]. In addition
to promoting chemoresistance, the ability of CLL cells to access
and be retained within the bone marrow (BM) and lymph node
(LN) microenvironment increases their chance of encountering
proliferative signals such as antigenic stimulation of the B cell
antigen receptor (BCR), or the T cell factors CD154 (CD40
ligand) and interleukin 4 (IL-4) [5], ultimately resulting in disease
progression.
Dasatinib is a tyrosine kinase inhibitor first developed as a
‘second-generation’ ATP-competitive inhibitor of the oncogenic
BCR-Abl kinase that characterises chronic myeloid leukaemia,
having a potency over three hundred-fold greater than imatinib
for the kinase [6]. Dasatinib also inhibits all Src-family tyrosine
kinases with an IC50 less than 1 nM, and other targets include c-kit
(IC50 5 nM), platelet-derived growth factor b (IC50 28 nM),
Bruton’s tyrosine kinase (BTK; IC50 5 nM) and Tec kinases (IC50
297 nM) [6,7]. Dasatinib results in significant clinical responses in
patients with imatinib-resistant chronic myeloid leukaemia [8],
and due to its’ multi-kinase targets, research interest has turned to
studying the drug in other haematological and solid-organ cancers.
Both our group and others have demonstrated that dasatinib
inhibits BCR signal transduction and blocks BCR-mediated
survival of CLL cells [9,10,11]. In solid tumour cell lines and
models, including melanoma [12], sarcoma [13], and colon
carcinoma [14] dasatinib has been shown to exert significant anti-
migratory effects, both in vitro and in vivo. Therefore, we were
interested to assess whether dasatinib disrupted CLL cell migration
in response to chemokine stimulation. Here, we show that
dasatinib significantly impairs migration of CLL cells toward
CXCL12, by inhibiting CXCR4 signaling.
Methods
Ethics Statement
Ethical approval was obtained from the West of Scotland
Research Ethics Committee. All patients who donated blood
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samples gave written informed consent in accordance with the
Declaration of Helsinki, and samples were anonymised during the
study.
Clinical Samples and Reagents
CLL cells were isolated from peripheral blood as previously
described [9]. Clinical details of patients used in these studies are
presented in Table 1; none of the patients had received
chemotherapy within the preceding 3 months. Immunohisto-
chemistry for ZAP-70 expression and FISH for 11q and 17p
deletions was performed by our local clinical pathology laboratory,
and results shown in Table 1. Dasatinib was purchased from LC
Laboratories (Woburn, MA, USA). As the peak plasma concen-
tration of dasatinib in patients following standard dosing is in the
region of 130 nM [15], dasatinib was used at a maximum
concentration of 100 nM in experiments.
Assessment of Actin Polymerisation
CLL cells (6106) were incubated in RPMI-1640 supplemented
with 0.5% BSA for 30 min with or without 100 nM dasatinib then
stimulated by the addition of 100 ng/ml CXCL12 (PeproTech EC
Ltd, London, UK). 100 ml aliquots were removed pre-stimulation,
and at 15, 60, 300, and 600 s after stimulation, and fixed/
permeabilised in 250 ml Fix/Perm solution (BD Biosciences,
Oxford, UK) according to manufacturer’s instructions. Cells were
then washed in Perm/Wash
TM
buffer (BD Biosciences) and stained
with AlexaFluorH 488-labelled phalloidin (Invitrogen Ltd., Paisley,
UK) for 10 min. Analysis was performed by acquiring 10,000
events on a FACSCantoII flow cytometer (BD Biosciences).
Assessment of Chemotaxis
CLL cells (56105) were incubated in 100 ml RPMI-1640/0.5%
BSA media with or without 1, 10, or 100 nM dasatinib for 30 min
prior to the assay. Cells were then transferred to the upper
chamber of a 6.5-mm diameter Transwell culture insert (CostarH,
Fisher Scientific UK.) and placed into wells containing 600 ml
media supplemented with or without 150 ng/ml CXCL12, and
incubated for 4 hr at 37uC. Thereafter, three 150 ml aliquots were
removed from each lower chamber for counting by flow
cytometry. For each aliquot the total number of events acquired
during 20 s on high flow setting was recorded.
Pseudoemperipolesis Assay
CLL cells (26106/ml) were treated with or without with
100 nM dasatinib for 30 min then transferred to collagen-coated
wells containing a confluent layer of M2-10B4 fibroblasts. Each
experimental condition was set-up in triplicate, and cells were then
incubated for 5 hr at 37uC in 5% CO2. Following removal of non-
migrated cells by thorough washing, the stromal cell layer was
trypsinised and stained with an anti-CD19 APC antibody (BD
Biosciences) to facilitate isolation of CLL cells by flow cytometry.
Pseudoemperipolesed CLL cells were counted by acquiring
CD19+ events on a FACSCantoII flow cytometer on high flow
setting for 30 s. An aliquot of the starting cell population was
similarly counted, to enable calculation of the percentage of CLL
cells able to transmigrate.
Assessment of Viability
CLL cell viability was assessed by staining with Annexin V
fluorescein isothicyanate and Viaprobe (BD Biosciences) as
previously described [9].
Immunoblotting
CLL cells (36106/ml) were incubated with or without 100 nM
dasatinib in RPMI 1640 containing 0.5% BSA for 30 min, then
left unstimulated or further treated with 100 ng/ml CXCL12 at
37uC for 3 or 10 min. Protein lysates were subsequently prepared
and analysed by immunoblotting as previously described [9]. All
antibodies used in western blotting were sourced from Cell
Signaling TechnologyH (Danvers, MA, USA) apart from phospho-
Lyn396, which was purchased from Epitomics (Cambridge, MA,
USA).
CLL Cell Proliferation Assays
To analyse cell division, CLL cells were stained with 1 mM
CFSE prior to culture. Cells (56105) were then co-cultured for up
to 12 days with NT-L murine fibroblasts stably transfected to
express CD154 [16] in media supplemented with 10 ng/ml IL-4
(the CD154/IL-4 system) in the presence or absence of 100 nM
dasatinib. Control cells, to which 50 ng/ml colcemid (Sigma
Aldrich, Dorset, UK) was added, were included to define the
undivided cell population; media and dasatinib was replenished
every 72 hr. To assess both cell divisions and absolute cell
numbers, cells were stained with an anti-CD19 APC antibody then
resuspended in 450 ml buffer to which 50 ml CountBright
TM
beads
(Invitrogen Ltd.) was added prior to flow cytometry. To assess cell
division, 10,000 CD19+ events were recorded for each sample on a
FACSCantoII flow cytometer and analysed with FACSDiva
software (BD Biosciences). Using the mean fluorescence intensity
(MFI) of CFSE in the colcemid control to define the gate
encompassing undivided cells, further gates were set for a
successive halving of MFI, to include cells that had undergone
cell division(s). To determine absolute cell counts, 5000 Count-







3 55 F A No Neg –
7 73 M C Yes Pos 11q–
12 59 F A No Neg –
18 63 F B Yes Pos 11q–
21 67 F C Yes Pos –
32 67 F B No Pos –
34 64 M B Yes Pos 11q–
35 68 M B No Pos –
36 76 M A Yes Pos 11q–
41 59 M A No Neg –
44 63 F A No Neg –
45 78 M B Yes Pos –
46 52 F A No Pos –
50 61 M C No Pos –
52 78 F B Yes Neg 11q–
64 64 M C Yes Neg –
62 84 F A Yes ND –
68 57 F A Yes Pos –
69 43 M A No Pos –
70 74 F C No Neg –
ND=not determined
doi:10.1371/journal.pone.0048929.t001
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Bright
TM
bead events were acquired. CLL cell counts were then
determined using a standard formula based on the ratio of CD19+
events to beads, following the manufacturer’s instructions.
Statistical Analysis
Data were analysed using the unpaired, 2-tailed, Student t test
(GraphPad Prism software, La Jolla, CA, USA).
Results and Discussion
Firstly, we assessed the effect of dasatinib pre-treatment on actin
polymerisation in response to CXCL12 stimulation. Dasatinib pre-
treatment notably reduced the basal level of actin polymerisation
within CLL cells, and also significantly blunted the initial increase
in polymerisation following CXCL12 stimulation (Figure 1A).
CLL cell migration towards CXCL12 was then assessed in a
transwell assay. Dasatinib reduced chemotaxis in a concentration-
dependent manner, with 100 nM dasatinib resulting in a mean
(6SEM) number of migrated cells of 3229 (6242) as compared to
4812 (6328) in untreated controls (Figure 1B; p,0.001).
Moreover, dasatinib significantly reduced the percentage of CLL
cells able to migrate beneath the CXCL12-expressing stromal cell
line M2-10B4 (Figure 1C; p= 0.02). No significant differences in
actin polymerisation or migration were observed between ZAP-70
positive and negative CLL cells in our study. This confirms a
previous report that found ZAP-70 positive CLL cells to be more
responsive to the chemokines CCL19 and CCL21, but not
CXCL12 [17]. As CXCL12 stimulation increases the viability of
CLL cells cultured in vitro [18], we were also interested to assess
whether dasatinib may inhibit the anti-apoptotic effect of
CXCL12. CLL cells were cultured for 48 hr in the presence and
absence of dasatinib, CXCL12, or both. CXCL12 significantly
increased the viability of cultured CLL cells, confirming previous
reports (Figure 1D). Dasatinib completely abrogated the anti-
apoptotic effect of CXCL12, with cell viability similar to that of
cells treated with dasatinib alone (Figure 1D).
As CXCR4 stimulation results in rapid activation of PI-3K and
ERK-MAPK in CLL cells [4,19,20], we next assessed the
activation status of these two signaling pathways following
CXCL12 stimulation in the presence or absence of dasatinib.
Dasatinib completely abrogated Akt phosphorylation, and par-
tially inhibited ERK activation (Figure 2A). There is substantial
evidence indicating that PI-3K/Akt signaling is a key regulator of
migration toward CXCL12 in CLL cells. Burger et al. showed that
Figure 1. Dasatinib inhibits actin polymerisation and migration of CLL cells in response to CXCL12. A: Analysis of the effect of dasatinib
on actin polymerization following CXCL12 treatment of CLL cells. Results are expressed relative to the untreated control prior to CXCL12 stimulation.
The graph shows the mean (6SEM) values for five independent experiments using different CLL samples (samples 7, 41, 45, 46 and 62). * indicates
p,0.05. B: The graph shows the effect of increasing concentrations of dasatinib on chemotaxis of CLL cells towards CXCL12. Data are expressed as
the average number (6SEM) of migrated cells from five independent experiments (samples 21, 35, 45, 46 and 62). C: The graph shows the
percentage of CLL cells able to migrate beneath a stromal cell layer (pseudoemperipolesis) in the presence or absence of dasatinib. Results are
expressed as the mean (6SEM) percentage of migrated cells in each condition (n = 8; samples 12, 18, 32, 46, 52, 64, 68 and 69). D: CLL cells (16106)
were incubated in conditions as shown for 48 hr, then apoptosis was assessed by Annexin/Viaprobe staining. The graph shows the mean (6SEM)
viabilities of cells, relative to the viability of untreated control cells (n = 6; samples 12, 36, 41, 44, 45 and 62).
doi:10.1371/journal.pone.0048929.g001
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the PI-3K inhibitor wortmannin reduced CLL cell migration
towards CXCL12, whilst MEK inhibition had no significant effect
[3]. More recently, specific PI-3K inhibitors have been shown to
inhibit actin polymerisation, chemotaxis, and pseudoemperipolesis
in response to CXCL12 [19,21]. We were next interested to
investigate the mechanism by which dasatinib may inhibit Akt
phosphorylation in CLL cells in response to CXCL12.
Dasatinib exerts its’ pro-apoptotic effects through inhibition of
kinases involved in BCR signaling, including Lyn and Syk
[7,9,10,11]. Here, we show that dasatinib inhibits Lyn autophos-
phorylation in the presence and absence of CXCL12 stimulation
(Figure 2B). Interestingly, the Src-family kinase Lyn has been
demonstrated to control migration of hematopoietic cells, with
chemotaxis of BM mononuclear cells from Lyn2/2 mice toward
CXCL12 impaired by over 75% [22]. Moreover, siRNA
knockdown of Lyn in primary CD34+ hematopoietic progenitor
cells reduced migration toward CXCL12 three to seven-fold over
controls [23]. Therefore Lyn inhibition may contribute to the anti-
migratory effect of dasatinib in CLL cells. Of note, the Src kinases
Lyn and Fyn interact directly with the p85 subunit of PI-3K
through their Src homology 3 (SH3) domains in a B cell
lymphoma cell line [24], and Lyn co-localizes with PI-3K in
HL-60 cells following CXCL12 stimulation [22]. Buchner et al.
recently demonstrated CXCL12 stimulation to induce phosphor-
ylation of Syk and Akt in CLL cells, which was abrogated by the
small molecule Syk inhibitor R406 [25]. R406 also significantly
reduced CLL cell migration toward CXCL12 [25,26]. Although
R406 has a number of off-target effects [27], a recent study
demonstrated two novel specific Syk inhibitors, PRT318 and
P505–15, to significantly reduce chemotaxis toward CXCL12 or
CXCL13 and inhibit pseudoemperipolesis in stromal co-culture
experiments [28].
Recently published data suggests that additional dasatinib target
kinases may also contribute to the overall anti-migratory effect.
BTK activation has been demonstrated following CXCL12
stimulation in a B-cell lymphoma cell line, and the small-molecule
BTK inhibitor PCI-32765 blocked CXCL12-induced ERK and
Akt phosphorylation in the same cell line [29] and primary CLL
cells [30]. Furthermore, PCI-32765 significantly reduced actin
polymerization and migration of primary CLL cells toward
CXCL12 and CXCL13 [29,30]. It is notable that the IC50 of
dasatinib for BTK is 5 nM [7]. In solid tumour cell lines, dasatinib
inhibits migration by blocking phosphorylation of Src and the
downstream target focal adhesion kinase (FAK) [12,13,14]. Of
note, Lopez-Guerra et al. recently demonstrated phosphorylation
of FAK in response to CXCL12 stimulation in CLL cells, and
inhibition of Src and FAK by the multikinase inhibitor sorafenib
correlated with reduced chemotaxis [31]. In summary, dasatinib
targets several key tyrosine kinases that regulate the migration of
CLL cells in response to chemokine stimulation, resulting in a
significant impairment of chemotaxis.
Clinical trials of kinase inhibitors targeting BCR signaling in
CLL have confirmed that the anti-migratory effects observed in
vitro also occur in vivo and contribute substantially to overall clinical
response. Hoellenriegel et al. reported that the PI-3K delta
inhibitor CAL-101 induced an early reduction in patient LN size
accompanied by a significant lymphocytosis that later resolved on
therapy [21], suggesting that CLL cells were mobilised from the
protective environment of the BM and LN to the peripheral blood
where they were then sensitive to the pro-apoptotic effects of the
inhibitor. A transient lymphocytosis is also observed in patients
responding to the orally-available Syk inhibitor fostamatinib
disodium [32], and the BTK inhibitor PCI-32765 [30] in reported
phase I/II trials. To date, there is only one published phase II trial
of dasatinib in CLL. In this small study, Amrein et al. reported
significant nodal responses to be achieved more frequently (9/15
patients) than a reduction in peripheral blood leucocytosis (4/15
patients) [33]. The authors postulated that dasatinib may
preferentially induce apoptosis of proliferating CLL cells. Of note,
we found no inhibitory effect of dasatinib on proliferation or
survival of CLL cells cultured for up to 12 days in the CD154/IL-4
system (Figure 3), an in vitro co-culture system that approximates
the in vivo microenvironment of proliferation centres [34]. These
data are consistent with previous reports that the pro-apoptotic
effect of dasatinib alone is lost on co-culture with stromal cells
expressing CD154 [9,35], but more importantly, this is the first
published report of the effect of dasatinib on CLL cell
proliferation. Our data therefore suggest that an in vivo anti-
migratory effect contributes to the overall clinical response to
dasatinib, as observed with the other targeted kinase inhibitors
described above. As dasatinib exhibits synergy with both
established and novel chemotherapeutic agents in the absence of
a protective microenvironment [9] our present data further
support the investigation of dasatinib in future combination
clinical trials.
Figure 2. Dasatinib inhibits key signaling events on CXCR4
stimulation. A: CLL cells were treated with or without 100 nM
dasatinib for 30 min, prior to stimulation with 100 ng/ml CXCL12.
Protein lysates were prepared at 3 and 10 min, and immunoblotting
performed to determine the level and phosphorylation of Akt and ERK.
One representative blot from three independent experiments is shown
(samples 35, 45 and 50). B: CLL cells were treated as above, and
immunoblotting for Lyn396 phosphorylation performed. The immuno-
blot shown is representative of three independent experiments
(samples 44, 45 and 70).
doi:10.1371/journal.pone.0048929.g002
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